Sana Biotechnology Stock Forecast
NASDAQ: SANAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SANA analyst consensus
Consensus (9 analysts)
none
Avg. price target
$8.43+202.15%
- Strong buy 2
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 9 Wall Street analysts covering Sana Biotechnology (2026-10-08), 8 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $8.43, with a high estimate of $12.00 and a low estimate of $6.00. The average target implies upside of 202.2% from the current price of $2.79.
The spread between the highest and lowest targets is 100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SANA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 22% |
| Buy | 6 | 67% |
| Hold | 1 | 11% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $6.00 | +115.05% |
| Average target | $8.43 | +202.15% |
| High target | $12.00 | +330.11% |